Haemonetics Corp. has a market cap of $1.43 billion; its shares were traded at around $56.84 with a P/E ratio of 20.7 and P/S ratio of 2.4. Haemonetics Corp. had an annual average earning growth of 10.6% over the past 10 years. GuruFocus rated Haemonetics Corp. the business predictability rank of 5-star.
HAE is in the portfolios of Jim Simons of Renaissance Technologies LLC, Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC, Steven Cohen of SAC Capital Advisors.
This is the annual revenues and earnings per share of HAE over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of HAE.
CEO Recent Trades:
- Sell:: President & CEO Brian Concannon sold 260 shares of HAE stock on 10/27/2009 at the average price of 53.86, the price of the stock has increased by 5.53% since.
CFO Recent Trades:
- Sell:: CFO & Vice President of Christopher J Lindop sold 107 shares of HAE stock on 10/26/2009 at the average price of 54.52, the price of the stock has increased by 4.26% since.
This is the insider trade history vs. stock price of HAE. For the complete insider trading history of HAE, click here.
Directors and Officers Recent Trades:
- Sell:: Chairman of the Board Brad Nutter sold 173,128 shares of HAE stock on 03/24/2010 at the average price of 57, the price of the stock has decreased by 0.28% since.
- Sell:: Director Lawrence C Best sold 50,000 shares of HAE stock on 02/18/2010 at the average price of 53.42, the price of the stock has increased by 6.4% since.
- Sell:: Director Lawrence C Best sold 50,000 shares of HAE stock on 02/17/2010 at the average price of 53.57, the price of the stock has increased by 6.1% since.
- Sell:: Chief Marketing Officer Peter M Allen sold 2,200 shares of HAE stock on 02/10/2010 at the average price of 52.56, the price of the stock has increased by 8.14% since.
- Sell:: VP, Corporate Affairs Alicia R Lopez sold 143 shares of HAE stock on 10/26/2009 at the average price of 54.38, the price of the stock has increased by 4.52% since.







RSS